Citations

Showing 10 of 108083 citations.

Length of Stay After Overlapping Surgery
Hyder, Joseph A. , Habermann, Elizabeth B. , Habermann, Elizabeth , Cima, Robert R.

Mayo Clinic

JAMA | December 5, 2017 | Volume: 318 | Issue: 21 | Pages: 2140

10.1001/jama.2017.16607 | PMID 29209713 Get It

Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity‐matched study
Charilaou, Paris , Devani, Kalpit , John, Febin , Kanna, Sowjanya, Ahlawat, Sushil , Young, Mark , Khanna, Sahil , Reddy, Chakradhar

Mayo Clinic

Journal of Gastroenterology and Hepatology | December 5, 2017 | Volume: 33 | Issue: 6 | Pages: 1227-1233

10.1111/jgh.14064 | PMID 29205514 Get It

AbstractBackground and AimAcute kidney injury (AKI) is used as a marker of severity in Clostridium difficile infection (CDI) patients. We estimated the true effect of AKI in inpatient mortality of CDI patients, as there are no large‐scale, population‐based, propensity‐matched studies evaluating AKI's effect in this patient cohort.MethodsA retrospective observational study utilizing the National Inpatient Sample from years 2003 to 2012, including all adults with CDI, excluding cases missing data on age, inpatient mortality or gender. Trends and CDI‐related complications as mortality predictors were assessed using survey‐weighted multivariable regression. We estimated AKI's independent effect by propensity‐matching, post‐stratifying by chronic kidney disease status, allowing for multiple comorbidity adjustment.ResultsA total of 2 859 599 patients with CDI were included, of which 896 122 (31.3%) had principal diagnosis of CDI. AKI prevalence was 22%. Mortality rate was 8.4%, while among AKI patients was higher (18.2%). In multivariable regression, AKI was associated with higher mortality (odds ratio [OR] = 3.16, 95% confidence interval [CI]: 3.02–3.30; P < 0.001), while after propensity matching, AKI increased mortality by 86% (OR = 1.86, 95% CI: 1.79–1.94; P < 0.001). CDI incidence increased by 1.8, together with the rate of AKI (12.6% in 2003 to 28.8% in 2012, P‐trend < 0.001). Despite increasing hospitalizations, mortality over the study period decreased to 7.2% (2012) from 9.0% (2003); P‐trend < 0.001.ConclusionHospital admissions of patients with CDI and concomitant AKI are increasing, but their inpatient mortality has improved over the study period. AKI is a significant contributor to mortality, independently of other comorbidities, complications, and hospital characteristics, emphasizing the need for early diagnosis and aggressive management in such patients.
Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis
Singh, Siddharth , Sandborn, William J. , Murad, M. Hassan , Singh, S , Murad, M Hassan , Fumery, Mathurin

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 5, 2017 | Volume: 47 | Issue: 2 | Pages: 162-175

10.1111/apt.14422 | PMID 29205406 Get It

SummaryBackgroundThere are limited data to inform positioning of agents for treating moderate‐severe ulcerative colitis (UC).AimTo assess comparative efficacy and safety of different therapies as first‐line (biologic‐naïve) and second‐line (prior exposure to anti‐tumour necrosis factor(TNF)‐α) agents for moderate‐severe UC, through a systematic review and network meta‐analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach.MethodsWe identified randomised controlled trials (RCTs) in adults with moderate‐severe UC treated with anti‐TNF agents, anti‐integrin agents and janus kinase (JAK) inhibitors, as first‐line or second‐line agents, and compared with placebo or another active agent. Efficacy outcomes were induction/maintenance of remission and mucosal healing; and safety outcomes were serious adverse events and infections. Network meta‐analyses were performed, and ranking was assessed using surface under the cumulative ranking (SUCRA) probabilities.ResultsIn biologic‐naïve patients (12 trials, no head‐to‐head comparisons), infliximab and vedolizumab were ranked highest for induction of clinical remission (infliximab: odds ratio [OR], 4.10 [95% confidence intervals [CI], 2.58‐6.52]; SUCRA,0.85; vedolizumab:SUCRA,0.82) and mucosal healing (infliximab:SUCRA,0.91; vedolizumab:SUCRA,0.81) (moderate QoE). In patients with prior anti‐TNF exposure (4 trials, no head‐to‐head comparisons), tofacitinib was ranked highest for induction of clinical remission (OR, 11.88 [2.32‐60.89]; SUCRA, 0.96) and mucosal healing (moderate QoE). Differences in trial design limited comparability of trials of maintenance therapy for efficacy. Vedolizumab was ranked safest in terms of serious adverse events (SUCRA, 0.91), and infection (SUCRA, 0.75) in maintenance trials.ConclusionsInfliximab and vedolizumab are ranked highest as first‐line agents, and tofacitinib is ranked highest as second‐line agent, for induction of remission and mucosal healing in patients with moderate‐severe UC, based on indirect comparisons. Head‐to‐head trials are warranted to inform clinical decision‐making with greater confidence.
Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
Enninga, Elizabeth Ann L. , Harrington, Susan M. , Creedon, Douglas J., Dong, Haidong , Dronca, Roxana , Ruano, Rodrigo , Dronca, Roxana S., Dong, Haidong , Enninga, Elizabeth Ann L , Markovic, Svetomir N.

Mayo Clinic

American Journal of Reproductive Immunology | December 5, 2017 | Volume: 79 | Issue: 2 | Pages: No page available

10.1111/aji.12795 | PMID 29205636 Get It

ProblemPregnancy requires balance between tolerance to the haploidentical fetus and the mother's ability to mount immune responses. There are parallels to this phenomenon that occur in metastatic cancer. We assessed soluble program death ligand‐1 soluble PD‐L1 (sPD‐L1) and galectin‐9 in the blood of pregnant women during gestation as these molecules are highly involved in immune suppression during cancer.Method of studyMaternal blood was collected from 30 primigravida women at monthly intervals during pregnancy, delivery and 6‐week post‐partum. Blood was analyzed for sPD‐L1 and galectin‐9 concentrations by ELISA. Term placentas were collected in formalin and IHC was completed for PD‐L1 and galectin‐9 expression.ResultsMaternal blood levels of sPD‐L1 (0.438 ng/mL) and galectin‐9 (1976 pg/mL) were elevated early in normal pregnancies compared to non‐pregnant controls (0.242 ng/mL and 773 pg/mL, respectively). sPD‐L1 increased throughout gestation, whereas galectin‐9 remained elevated until parturition; both proteins returned to control levels post‐partum. Women carrying male fetuses had significantly higher galectin‐9 levels, but not sPD‐L1, than those carrying females (2263 pg/mL vs 1874 pg/mL; P = .0005). Trophoblast cells of the term placenta coexpress galectin‐9 and PD‐L1.ConclusionImmune‐regulatory molecules galectin‐9 and sPD‐L1 increased during pregnancy and may play a role in immune tolerance that is critical for the fetus.
A data-driven approach for addressing the lack of flow waveform data in studies of cerebral arterial flow in older adults*
Durka, Michael J. , Wong, Isaac H, Kallmes, David F. , Pasalic, Dario , Mut, Fernando , Jagani, Manoj, Blanco, Pablo J. , Robertson, Anne M. , Robertson, Anne M , Cebral, Juan R.

Mayo Clinic

Physiological Measurement | December 5, 2017 | Volume: 39 | Issue: 1 | Pages: 015006

10.1088/1361-6579/aa9f46 | PMID 29205172 Get It

Abstract Objective : Blood flow waveforms—essential data for hemodynamic modeling—are often in practice unavailable to researchers. The objectives of this work were to assess the variability among the waveforms for a clinically relevant older population, and develop data-based methods for addressing the missing waveform data for hemodynamic studies. Approach : We analyzed 272 flow waveforms from the internal carotid arteries of older patients (73 ± 13 yr) with moderate cardiovascular disease, and used these data to develop methods to guide new approaches for hemodynamic studies. Main results : Profound variations in waveform parameters were found within the aged population that were not seen in published data for young subjects. Common features in the aged population relative to the young included a larger systole-to-diastole flow rate ratio, increased flow during late systole, and absence of a dicrotic notch. Eight waveforms were identified that collectively represent the range of waveforms in the older population. A relationship between waveform shape and flow rate was obtained that, in conjunction with equations relating flow rate to diameter, can be used to provide individualized waveforms for patient-specific geometries. The dependence of flow rate on diameter was statistically different between male and female patients. Significance : It was shown that a single archetypal waveform cannot well-represent the diverse waveforms found within an aged population, although this approach is frequently used in studies of flow in the cerebral vasculature. Motivated by these results, we provided a set of eight waveforms that can be used to assess the hemodynamic uncertainty associated with the lack of patient-specific waveform data. We also provided a methodology for generating individualized waveforms when patient gender, age, and cardiovascular disease state are known. These data-driven approaches can be used to devise more relevant in vitro or in silico intra-cranial hemodynamic studies for older patients.
The Pharmacist as a Member of the Cardiopulmonary Resuscitation Team
Schwerman, Earl A., Schwartau, Neal, Thompson, Conrad O., Didier, Edward P.

Mayo Clinic

Drug Intelligence & Clinical Pharmacy | December 5, 2017 | Volume: 7 | Issue: 7 | Pages: 298-308

10.1177/106002807300700702 Get It

Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial
Kessler, Maya , Carter, Rickey E. , Cook, David A. , Kor, Daryl J. , Pencille, Laurie J., Scheitel, Marianne, Chaudhry, Rajeev , Kessler, Maya Elizabeth, Kor, Daryl Jon, McKie, Paul M. , Scheitel, Marianne R, Carter, Rickey E

Mayo Clinic

BMJ Open | December 5, 2017 | Volume: 7 | Issue: 12 | Pages: e019087

10.1136/bmjopen-2017-019087 | PMID 29208620 Get It

Introduction Clinical practice guidelines facilitate optimal clinical practice. Point of care access, interpretation and application of such guidelines, however, is inconsistent. Informatics-based tools may help clinicians apply guidelines more consistently. We have developed a novel clinical decision support tool that presents guideline-relevant information and actionable items to clinicians at the point of care. We aim to test whether this tool improves the management of hyperlipidaemia, atrial fibrillation and heart failure by primary care clinicians. Methods/analysis Clinician care teams were cluster randomised to receive access to the clinical decision support tool or passive access to institutional guidelines on 16 May 2016. The trial began on 1 June 2016 when access to the tool was granted to the intervention clinicians. The trial will be run for 6 months to ensure a sufficient number of patient encounters to achieve 80% power to detect a twofold increase in the primary outcome at the 0.05 level of significance. The primary outcome measure will be the percentage of guideline-based recommendations acted on by clinicians for hyperlipidaemia, atrial fibrillation and heart failure. We hypothesise care teams with access to the clinical decision support tool will act on recommendations at a higher rate than care teams in the standard of care arm. Ethics and dissemination The Mayo Clinic Institutional Review Board approved all study procedures. Informed consent was obtained from clinicians. A waiver of informed consent and of Health Insurance Portability and Accountability Act (HIPAA) authorisation for patients managed by clinicians in the study was granted. In addition to publication, results will be disseminated via meetings and newsletters. Trial registration number NCT02742545 .
Methylprednisolone acetate induces, and Δ7-dafachronic acid suppresses, Strongyloides stercoralis hyperinfection in NSG mice
Patton, John B., Bonne-Année, Sandra, Deckman, Jessica M., Hess, Jessica A., Torigian, April, Nolan, Thomas J. , Wang, Zhu , Kliewer, Steven A. , Durham, Amy C. , Lee, James J. , Eberhard, Mark L., Mangelsdorf, David J. , Lok, James B. , Abraham, David

Mayo Clinic

Proceedings of the National Academy of Sciences | December 4, 2017 | Volume: 115 | Issue: 1 | Pages: 204-209

10.1073/pnas.1712235114 | PMID 29203662 Get It

Significance The intestinal parasite Strongyloides stercoralis infects an estimated 100 million people. This nematode’s unique ability to autoinfect its host enables it to persist for decades undetected and to progress to a potentially fatal hyperinfection that often is induced by glucocorticoid treatment. We report a mouse model, involving the NSG strain, that recapitulates all forms of human strongyloidiasis. Even in severely immunocompromised NSG mice, glucocorticoid treatment was required for autoinfection, raising intriguing questions about the mechanism of glucocorticoid action. Notably, administering a nematode-derived steroid, Δ7-dafachronic acid, which acts through a receptor within S. stercoralis to regulate parasite development, significantly diminished autoinfection in glucocorticoid-treated NSG mice. This opens the possibility of new chemotherapy for hyperinfective strongyloidiasis, targeting the parasite’s own steroid hormone mechanisms.
Informing vs Changing the Practice of Carotid Revascularization
Meschia, James F.

Mayo Clinic

JAMA Neurology | December 4, 2017 | Volume: 75 | Issue: 1 | Pages: 20

10.1001/jamaneurol.2017.3298 | PMID 29204661 Get It